Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GS 9450 in Adults with Non-Alcoholic Steatohepatitis
2008-002361-31Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing GS 9450 with Placebo (2 arms). Primary endpoints: Safety and tolerability of GS 9450, Pharmacokinetics of GS 9450 and metabolites and 1 more. Started Jun 2008; status: completed.
02
Drugs
nivocasan
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2008-002361-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002361-31.